Familial clustering and presumed genetic risk for type 2 diabetic (T2D) and non-diabetic end-stage kidney disease (ESKD) appear strong in African Americans. Examination of exome sequencing data in African American T2D-ESKD cases and non-diabetic non-nephropathy controls identified two low frequency variants in the RREB1 gene, a repressor of the angiotensinogen (AGT) gene previously associated with kidney function, as being associated with T2D-ESKD: rs9379084 (p=0.00087, OR=0.26; D1171N) and rs41302867 (p=0.00078, OR=0.21; splice site variant). Rs41302867 replicated association in an independent sample of African Americans with T2D-ESKD (rs41302867 p=0. 
Introduction
Ample evidence supports genetic influences on susceptibility to complex diseases such as endstage kidney disease (ESKD). This is especially true in African Americans where incidence rates of ESKD are 3.5 fold higher than in European Americans and twice that of Native Americans and Hispanic Americans (1). Following adjustment for socioeconomic status and environmental influences, incidence rates and familial aggregation of ESKD remain markedly higher among African Americans compared to other ethnic groups (2, 3) . The apolipoprotein L1 gene (APOL1) G1 and G2 alleles, present in those of West African descent, explain a substantial portion of the ethnic disparity in HIV-associated collapsing glomerulopathy, idiopathic focal segmental glomerulosclerosis (FSGS), and hypertension-attributed ESKD (4, 5) . While these APOL1 variants account for roughly 70% of the ethnic differences in risk for non-diabetic forms of ESKD (non-T2D ESKD), they fail to account for the excess risk of type 2 diabetic ESKD (T2D-ESKD) in African Americans (6) . It is likely that other genetic loci contribute to T2D-ESKD (and non-T2D ESKD) risk in the African American population (7).
Next-generation exome sequencing (NGES) is a powerful technology which facilitates detailed exploration of previously untested genetic regions, aiding in the identification of genetic variations in coding sequences of genes for disease association. We utilized NGES data to survey the RREB1 gene (ras-responsive element binding protein-1), an upstream regulator of the Renin-Angiotensin System (RAS). Multiple splice variants of RREB1, also known as Finb, have been shown to act as sequencespecific transcriptional repressors of the angiotensinogen (AGT) gene (8) . A genome-wide association study (GWAS) published by the CHARGE consortium identified an association between an RREB1 variant and estimated glomerular filtration rate (eGFR), and an intronic variant near the RREB1 locus has evidence of interaction with the APOL1 gene in African Americans with non-T2D ESKD (9, 10) . Given the a priori functional and genomics data, we hypothesized that genetic variations in RREB1 may contribute to nephropathy susceptibility in the African American population. 
Results
The impact of genetic variations in RREB1 modulating T2D-ESKD, non-T2D ESKD, and T2D (in the absence of nephropathy) susceptibility in the general African and European American population was investigated using a multistage study design (Figure 1) . Initially, RREB1 was assessed in exome sequence data from 529 African American T2D-ESKD cases and 535 non-diabetic non-nephropathy controls (Discovery). The two signals from RREB1, in high linkage disequilibrium (LD; r 2 =0.63), were amongst the top 58 hits across the entire exome with the strongest biological plausibility for association.
This Discovery sample provides a unique resource, albeit with limited power, which results in nominal evidence of association. Thus, based on the signal from the Discovery study coupled with a priori genetic associations (APOL1 interaction, prior association with eGFR) and biological plausibility, we pursued further investigation of RREB1 in additional DNA samples.
The Discovery study was followed by testing in an independent African American T2D-ESKD case-control sample (Replication), followed by analysis in African American non-T2D-ESKD cases, and
African American T2D-only cases (i.e. T2D, without nephropathy). RREB1 variants were also tested in European American case-control samples with T2D-ESKD and T2D lacking nephropathy.
Characteristics of the African American and European American samples are detailed in Tables 1   and 2 , respectively. African American Discovery T2D-ESKD cases were broadly similar to those in the Replication T2D-ESKD study for all characteristics. The population-based controls for the Discovery and Replication studies are, on average, younger than the cases in the Discovery and Replication studies;
however, the age of T2D diagnosis in the cases is younger than the mean age of the population-based controls at enrollment. All cohorts except African American non-T2D ESKD cases had a larger percentage of females. The distributions of body mass index (BMI) were similar across cohorts, with the non-T2D ESKD cohort having the lowest mean BMI. As with African American cases, European
American T2D-ESKD and T2D-only cases tended to be older than controls, but the age at T2D diagnosis (Table 3) . A trend toward T2D association was observed in African Americans for rs41302867 (Table 3) .
We next genotyped RREB1 variants rs9379084 and rs41302867 in 637 European Americans with T2D-ESKD and 1020 European American population-based controls (non-T2D, non-nephropathy (Table 3 ). These protective variants were found at greater MAF in European Americans, and consistent ORs were observed between African Americans and European Americans. In European
Americans with T2D in the absence of nephropathy, rs9379084 was modestly associated (p=0.014, OR=0.65 [0.48, 0.89]) and a trend for association with rs41302867 was observed ( Table 3) .
A meta-analysis combing European American and African American data was performed for
T2D-ESKD (all T2D-ESKD samples) and "all cause" ESKD (all T2D-ESKD samples + African
American non-T2D ESKD cases) using METAL. After correction for multiple comparisons, p-values of 3.52x10 -7 and 3.70x10 -5 were observed for rs9379084 and rs41302867, respectively, under Model 2 for T2D-ESKD association (Table 4A ). In the "all cause" ESKD meta-analysis, which includes all T2D-ESKD samples in addition to the 1,705 African Americans with non-T2D ESKD, p-values of 8.74x10 -7 and 6.58x10 -6 were observed for rs9379084 and rs41302867, respectively, under Model 2 (Table 4B) .
Finally, in an effort to determine whether other putatively functional RREB1 SNPs were associated with T2D, T2D-ESKD, or non-T2D ESKD in African or European Americans, an additional 16 variants not found in the Discovery NGES Study were genotyped (Supplementary Table 4 ). These variants were selected based on their amino acid change, location in transcription factor binding sites, and MAF discrepancies between African and European Americans. Modest associations were observed for several variants after correction for multiple testing (Supplementary Table 6 ).
Discussion
We tested whether genetic variations in RREB1, one of the top signals in a T2D-ESKD NGES Discovery study with the strongest a priori biological and genomic plausibility as a candidate gene, were associated with susceptibility to common forms of ESKD in general African and European American populations. Results in these groups with different population ancestry were consistent, but complex.
Results consistently revealed that rs9379084 and rs41302867 were associated with protection from T2D- Tables 5 and   6 ). Together, these observations appear consistent given the complex structure and function of the RREB1 gene.
RREB1 is a large gene spanning 144 kB with at least 12 isoforms. Amino acid (AA) lengths for isoforms range from 4 AAs with 1 coding exon (RREB1-12) to 1742 AAs and 10 coding exons resulting in a protein product with 15 C2H2 zinc finger domains (RREB1-1). These longer isoforms of RREB1, previously termed "Finb" and including RREB1-1 ("Finb 188"), have been shown to repress expression of the AGT gene (8) . Relevant to nephropathy susceptibility, RREB1 polymorphisms reportedly interact with APOL1 and associate with kidney function (9, 10). Recent GWAS implicated RREB1 with fat distribution and fasting glucose, effects potentially related to the observed T2D associations (11, 12) . A T2D locus was recently identified in the RREB1-SSR1 gene region (13) .
The majority of studies evaluating RREB1 have focused on its role in oncology, as this transcription factor induces expression of p53 and represses p16 (14, 15) . The roles RREB1 plays in nononcogenic pathologies are less well studied, as are isoform-specific actions of RREB1. Aside from a study which documented larger transcripts of RREB1 repressing AGT expression, only one other study examined isoform-specific actions of RREB1 in urologic cancer (8, 16) . A large consortia recently published a meta-analysis with >80,000 individuals that located an association between a SNP in SSR1
(rs9505118) and T2D (13) . The authors reported that this SNP, although in SSR1, was part of the RREB1-SSR1 gene region. Finally, the association of an RREB1 SNP with eGFR in a CHARGE consortium GWAS was reported in supplementary data (9) . have associated RREB1 with fat distribution and fasting glucose levels (11, 12) . Thus, variations in RREB1 may impact disparate phenotypes including predisposition to T2D and ESKD related to both diabetic and non-diabetic etiologies in multiple population ancestral groups.
In addition to establishing genetic association for RREB1 in T2D-ESKD and non-T2D ESKD, and nominal evidence of association in related phenotypes, this study provides genetic insights into the disproportionate burden of T2D and ESKD borne by the African American community. Our data suggests that after centuries of admixture between European and African Americans, common protective variants (rs41302867 and rs9379084) were transferred from European Americans to African Americans. These differences in protective MAF may contribute to the disproportionate burden of T2D-ESKD and non-T2D ESKD borne by the African American community compared to other population ancestries. Results from this study approach, but do not meet genome-wide significance for T2D-ESKD. This is likely a limitation of our power reflected in the sample size and MAFs in African Americans.
This study demonstrates how a single gene with numerous splice variants may influence seemingly unrelated pathologies including T2D, T2D-ESKD, ESKD, hypertension, and malignancy. The ability of one gene to modulate a range of clinically relevant phenotypes warrants further investigation into pharmacologic targets which can exploit these pleiotropic properties. Finally, this study validates the effectiveness of NGES coupled with pragmatic, biological data and a priori knowledge of the pathology (eg, prioritizing variants based on allelic discrepancies between disproportionately affected populations)
to aid in the discovery of clinically relevant genetic variants.
Materials & Methods

Study Participants
Recruitment and sample collection procedures have been reported (6, 27 Recruitment and sample collection for European Americans with T2D-ESKD was performed as above controls were recruited from medicine clinics at WFSM (non-nephropathy, non-T2D population based controls).
African American non-diabetic (non-T2D) ESKD cases
African American non-T2D ESKD cases lacked diabetes (or diabetes developed after initiating renal replacement therapy). ESKD was attributed to chronic glomerular disease (e.g., FSGS), HIVassociated nephropathy, "hypertension-attributed", or unknown cause. Patients with ESKD due to 
African American T2D (non-nephropathy) samples
African Americans with T2D but lacking nephropathy were recruited from a previously published African American T2D GWAS study (27) , as well as internal medicine clinics at WFSM. Diabetic controls were receiving insulin or oral agents, had a HbA1c >6.5% or a fasting plasma glucose >126 mg/dl, and serum creatinine concentration <1.5 mg/dl (men) or 1.3 mg/dl (women). All T2D-only nonnephropathy controls in this study had an eGFR >60 ml/min/1.73m 2 and a urine albumin:creatinine ratio
European American T2D (non-nephropathy) samples
European Americans with T2D but lacking nephropathy were recruited from the Diabetes Heart Study (DHS) at WFSM. These diabetic controls were receiving insulin or oral agents, had a HbA1c
>6.5% and a fasting plasma glucose >126 mg/dl, and serum creatinine concentration <1.5 mg/dl (men) or 1.3 mg/dl (women). All T2D-only non-nephropathy controls in this study had an eGFR >60 ml/min/1.73m 2 and a UACR <60 mg/g.
Sample Preparation, Genotyping, and Quality Control African American T2D-ESKD T2D-GENES Discovery cases and controls
Exome sequencing data was provided by the T2D-GENES consortium for the 529 African American T2D-ESKD cases and 535 African American population based controls from WFSM.
Targeted Genotyping
Targeted genotyping of RREB1 (RefSeq NM_001003699.3) variants rs9379084 and rs41302867
were performed across all cohorts utilizing the Sequenom MassArray system (Sequenom, San Diego, CA)
in the Center for Genomics and Personalized Medicine Research at WFSM. SNPs were PCR-amplified using primers designed in MassARRAY Assay Design 3.1 (Sequenom, San Diego, CA) and genotypes were analyzed using MassARRAY Typer (Sequenom). Call rates >97% were achieved with the exception of rs77510523 which achieved >97% call rates in cases but 95% call rate in controls; quality control was ensured using blind duplicates within each cohort of samples (100% concordance rate).
Locus-wide analysis
The 1000 Genomes Project (ASW, YRI, LWK), Exome Variant Server (NHLBI), and RegulomeDB (28; http://regulome.stanford.edu/) were mined for additional rare (<0.5%), low (MAF 0.5-5%), and common (MAF >5%) frequency RREB1 (RefSeq NM_001003699. European Americans, where admixture and APOL1 are not applicable). These tests were computed using the SNPGWA program (http://www.phs.wfubmc.edu/public_bios/sec_gene/downloads.cfm).
Conditional Analyses
Conditional analyses were run on PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) v1.07. combine data from African and European Americans.
Meta-Analysis
Multiple Comparisons
For each analysis with rs9379084 and rs41302867, a multiple comparison adjustment for two SNPs was implemented. In the locus wide analysis a multiple comparison adjustment for 12 SNPs was used in African Americans (three failed QC) and 5 SNPs for European Americans (four failed QC and
five were unable to be tested in single-SNP association testing due to low MAF).
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